Literature DB >> 9390033

Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens.

B S Verbeek1, S S Adriaansen-Slot, G Rijksen, T M Vroom.   

Abstract

In 20-30 per cent of human breast cancers, the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and c-erbB2 are overexpressed. This overexpression leads to increased mitogenic signalling and is correlated with poor prognosis. Overexpression of associated adaptor proteins, like Grb2, can also induce upregulation of signalling pathways. In this study, the expression of the Grb2 adaptor protein was determined in both normal human breast tissue and mammary cancers, using immunoblotting experiments and immunostaining on paraffin-embedded tissue sections. Both biochemical and immunohistochemical techniques revealed overexpression of Grb2 in all breast cancer specimens. In addition, although Grb2 protein is described as localized in the cytoplasm, it can also be detected in the nucleus, both in normal and in tumour breast tissue. In tumour breast tissue, 58 per cent of Grb2 protein is found in the nucleus, while 37 per cent is detected in the cytoplasm. In normal breast tissue, 22 per cent of Grb2 is found in the nucleus and 70 per cent in the cytoplasm. These findings indicate that in human breast cancer, Grb2 is overexpressed and appears to be predominantly localized in the nucleus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390033     DOI: 10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.0.CO;2-Y

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  23 in total

1.  The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.

Authors:  Eric Haines; Caroline Saucier; Audrey Claing
Journal:  J Biol Chem       Date:  2014-01-09       Impact factor: 5.157

2.  The null oncogene hypothesis and protection from cancer.

Authors:  M P Davenport; R L Ward; N J Hawkins
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

3.  Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.

Authors:  Brunilde Gril; Michel Vidal; Franck Assayag; Marie-France Poupon; Wang-Qing Liu; Christiane Garbay
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

4.  Live-cell fluorescence imaging reveals high stoichiometry of Grb2 binding to the EGF receptor sustained during endocytosis.

Authors:  Arola Fortian; Alexander Sorkin
Journal:  J Cell Sci       Date:  2013-11-20       Impact factor: 5.285

5.  Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein.

Authors:  M J Rauh; V Blackmore; E R Andrechek; C G Tortorice; R Daly; V K Lai; T Pawson; R D Cardiff; P M Siegel; W J Muller
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

6.  Proteomic snapshot of breast cancer cell cycle: G1/S transition point.

Authors:  Milagros J Tenga; Iulia M Lazar
Journal:  Proteomics       Date:  2013-01       Impact factor: 3.984

Review 7.  Grb2 signaling in cell motility and cancer.

Authors:  Alessio Giubellino; Terrence R Burke; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

8.  Overexpression of GRB2 is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Li-Yan Li; En-Min Li; Zhi-Yong Wu; Hui-Hui Cao; Jin-Hui Shen; Xiu-E Xu; Bo Chen; Jian-Yi Wu; Li-Yan Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation.

Authors:  Stephanie J Moeller; Elizabeth D Head; Robert J Sheaff
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

10.  Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.

Authors:  Amy J Galliher-Beckley; William P Schiemann
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.